Higher-dose palopegteriparatide for hypoparathyroidism
Part of Hormones & metabolism clinical trials.
This trial is for adults with hypoparathyroidism who are already taking a drug called palopegteriparatide (TransCon PTH) at a certain dose. It tests whether higher doses of this drug can better control calcium levels and reduce the need for other supplements.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have hypoparathyroidism (from surgery, autoimmune, genetic, or unknown cause) for at least 6 months.
- You are currently taking palopegteriparatide (TransCon PTH) at 30 micrograms per day or more.
- Your kidney function is at least 30% of normal.
- You are not pregnant or breastfeeding.
- You do not have any other condition that affects calcium levels, like pseudohypoparathyroidism.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug called Canvuparatide against a placebo to see if it can help adults with a condition called hypoparathyroidism, where the body doesn't make enough parathyroid hormone. The goal is to improve calcium levels and reduce the need for high-dose calcium and vitamin D supplements.
This study tests a new medicine called palopegteriparatide for teenagers with long-term hypoparathyroidism (low parathyroid hormone). The medicine is given as a daily injection and aims to help control calcium levels.
This trial tests a new treatment to help people with hypoparathyroidism (a condition where your body doesn't make enough parathyroid hormone, causing low calcium levels) manage their calcium better. It aims to reduce the need for calcium and vitamin D supplements.
This trial tests whether a donated parathyroid gland can help people with low parathyroid hormone (hypoparathyroidism) control their calcium levels and reduce symptoms. Participants will receive transplant and short-term immune-suppressing drugs.
This trial tests a new medicine called EXT608 for adults with hypoparathyroidism. It aims to see if this medicine can help manage calcium levels better than current treatments.
This study tests a new medicine called encaleret for people with chronic hypoparathyroidism, a condition where the body has too little parathyroid hormone, leading to low calcium levels. The medicine aims to improve calcium balance and reduce the need for daily calcium and vitamin D supplements.
Hear when a new Hypoparathyroidism trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.